Carboplatin with or without nivolumab in metastatic triple-negative breast cancer: a randomized phase II trial - PubMed
2 days ago
- #Clinical Trial
- #Immunotherapy
- #Breast Cancer
- This randomized phase II trial tested carboplatin with or without nivolumab in metastatic triple-negative breast cancer (mTNBC).
- No significant improvement in progression-free survival (PFS) was found overall for the combination versus carboplatin alone.
- However, PD-L1-positive patients showed a trend toward better outcomes with the combination therapy.
- Safety profiles were comparable between the two treatment arms, with grade 3+ adverse events common in both.
- Potential biomarkers for immune checkpoint inhibitor response were identified, including high mutational burden and interferon-gamma signaling.